Curaleaf Laboratories has announced the launch of the UK’s first CE-certified liquid medical cannabis inhaler, aiming to address growing patient and clinical demand for a discreet and reliable inhalation method.
The Curaleaf Que Medical Inhalation Device (QMID), designed in partnership with Jupiter Research LLC, will be available on prescription to all UK medical cannabis clinics.
Its new rechargeable device uses Curaleaf’s already available EU-GMP liquid extract cartridges, and has a minimum lifespan of six months from first use, delivering up to 240 inhalations with a 1.0mL cartridge.
QMID has been purpose-built from the ground up as a clinical device, and represents the first CE-certified device of its kind to hit the UK market.
This means that the inhaler has passed rigorous European regulatory scrutiny regarding safety, reliability and repeatability across multiple use cases, and is officially deemed a Class IIa device under the EU Medical Device Regulation.
Aside from giving both prescribers and patients confidence in its therapeutic suitability and regulatory compliance, this focus on clinical utility means that the quantity of medication delivered has been measured using internationally recognised criteria, ensuring reliable delivery across all administrations.
Activated upon inhalation, the lack of buttons or menus means the device is simple to use, discreet and well-suited for both clinical supervision and home use for eligible patients who are appropriate for inhaled cannabis medicines.
Jonathan Hodgson, UK Managing Director at Curaleaf International, commented: “For the first time, inhaled liquid cannabis can be administered with controlled precision through a registered handheld device — giving prescribers and patients new confidence in treatment delivery.
“Unlike unregulated or consumer-grade vaporisers, this device is purpose-built for clinical use, with standardised delivery, medical-grade components, and compatibility with formulations that meet European Pharmacopoeia standards.”
READ MORE: Curaleaf International’s Strategic Moves in Europe: Exclusive Insights from Juan Martinez
The inhaler adds to Curaleaf’s existing product range in the UK, which includes oils, dried flower, capsules, pastilles, topicals and vaporisation products. The company is also working with regulators in Germany, Poland, Australia and other markets to secure approvals for the new device.
Curaleaf International continues to collaborate with regulators, healthcare providers and pharmacists across multiple regions, aiming to expand access to cannabinoid-based medicines in line with evolving clinical frameworks.
Juan Martinez, International CEO at Curaleaf, said: “The launch of this certified Curaleaf device reflects the next phase of innovation and positions Curaleaf at the forefront of a differentiated, pharma-grade delivery platform that addresses growing global demand for precision cannabis therapies.
“It’s part of our wider mission to make medical cannabis more accessible, more consistent, and integrated into mainstream healthcare systems.”
